Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2007-02-01
2010-11-02
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S197110, C424S274100
Reexamination Certificate
active
07824688
ABSTRACT:
Anti-glucan antibodies have been found to be protective against systemic fungal infection withC. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterised in that, when administered to a mammalian recipient, the composition elicits protective anti-glucan antibodies but does not elicit antibodies which inhibit the protective efficacy of the anti-glucan antibodies. The glucan may be presented on the surface of a protease-treated microbial cell or may be presented as a protein-glucan conjugate. The glucan may be substituted by a glucan mimotope, a peptidomimetic of a glucan mimotope, or nucleic acid encoding a mimotope. Anti-glucan-antibodies show broad spectrum microbicidal activity. β-glucans are preferred, particularly those containing one or more β-1,6 linkages.
REFERENCES:
patent: 5306492 (1994-04-01), Porro
patent: 6248329 (2001-06-01), Chandrashekar et al.
patent: 6309642 (2001-10-01), Cutler et al.
patent: 09-309842 (1997-12-01), None
patent: WO 95/30022 (1995-11-01), None
patent: WO 96/28476 (1996-09-01), None
patent: WO 99/55715 (1999-11-01), None
Adachi, et al., “Preparation and Antigen Specificity of an Anti-(1->3)-Beta-D-Glucan Antibody,”Biological and Pharmaceutical Bulletin 17(11):1508-1512 (1994).
Bromuro, et al., “Interplay Between Protective and Inhibitory Antibodies Dictates the Outcome of Experimentally Disseminated Candidiasis in Recipients of aCandida abicansVaccine,”Infection and Immunity 70(10):5462-5470 (2002).
Casadevall, et al., “Antibody Immunity and Invasive Fungal Infections,”Infection and Immunity 63(11):4211-4218 (1995).
Deepe, “Prospects for the Development of Fungal Vaccines,”Clinical Microbiology Reviews 10(4):585-596 (1997).
Derwent Abstract for “Method Produce Cell Wall Skeleton Powder Red Norcia,”Derwent Publications Ltd., London, GB, One page (1994) XP002264615.
Kieber-Emmons, “Peptide Mimotopes of Carbohydrate Antigens,”Immunologic Research 17(1-2):95-108 (1998).
Kieber-Emmons, et al., “Cutting Edge:DNA Immunization with Minigenes of Carbohydrate Mimotopes Induce Functional Anti-Carbohydrate Antibody Response,”Journal of Immunology 165(2):623-627 (2000).
Kondori, et al., “Candida albicansCell Wall Antigens for Serological Diagnosis of Candidemia,”Medical Mycology 41(1):21-30 (2003).
Masuzawa, et al., “SolubilizedCandidaCell Wall Beta-Glucan, CSBG, is an Epitope of Natural Human Antibody,”Drug Development Research 58(2):179-189 (2003).
Miura, et al., “Antigen-Specific Response Of Murine Immune System Toward A Yeast Beta-Glucan Preparation, Zymosan,”FEMS Immunol Med Microbiol 24:131-139 (1999).
Ohno, et al., “Solubilization Of Yeast Cell-Wall Beta-(1->)-D-Glucan by Sodium Hypochlorite Oxidation And Dimethyl Sulfoxide Extraction,”Carbohydrate Res 316:161-172 (1999).
Patent Abstracts of Japan, “Cosmetic” vol. 012, No. 312 (C-523), One Page. (1988).
Ross, et al., “Therapeutic Intervention With Complement and Beta-Glucan in Cancer,”Immunopharmacology 42(1-3):61-74 (1999).
Tokunaka, et al., “Immunopharmacological and Immunotoxicological Activities of a Water-Soluble (1->3)-Beta-D-Glucan, CSBG from Candidate spp,”Int J Immunopharm 22(5):383-394 (2000).
Torres-Bauza, et al., “Protoplasts From Yeast And Mycelial Forms OfCandida albicans,”J Gen Microbiol 119:341-349 (1980).
Tzianabos, “Polysaccharide Immunomodulators as Therapeutic Agents: Structural Aspects and Biological Function,”Clinical Microbiology Reviews 13(4):523-533 (2000).
Tzianabos, et al., “Protection Against Experimental Intraabdominal Sepsis By Two Polysaccharide Immunomodulators,”J Infect Dis 178:200-206 (1998).
Casadevall, et al., “Antibody-Mediated Protection Through Cross-Reactivity Induces A Fungal Heresy Into Immunological Dogma,”Inf Immun 75(11):5074-5078 (2007).
Honey, “β-Glucan Conjugate Provides Protection,”Nat Rev Immunol 4:814 (2005).
Rachini, et al., “An Anti-B-Glucan Monoclonal Antibody Inhibits Growth And Capsule Formation OfCryptococcusNeoformans In Vitro And Exerts Therapeutic, Anticryptococcal Activity in Vivo,”Inf Immun—75(11):5085-5094 (2007).
Ross, et al., “Therapeutic Intervention With Complement And β-Glucan in Cancer,”Immunopharmacology 42:61-74 (1999).
Sadamoto, et al., “Evidence For Interference By Immune Complexes In The Serodignosis Of Cryptococcosis,”Microbiol Immunol 37(2):129-133 (1993).
Tokunaka, et al., “Immunopharmacological and Immunotoxicological Activities Of A Water-Soluble (1→3)-βGlucan, CSBG FromCandidaspp,”Int J Immunopharm 22:383-394 (2000).
Torosantucci, et al., “A Novel Glyco-Conjugate Vaccine Against Fungal Pathogens,”J Exp Med 202(5):597-606 (2005).
Bromuro et al., “Beta-glucan-CRM197 Conjugates as Candidates Antifugal Vaccines,”Vaccine2010, 28:2615-2623 (2010).
Pietrella et al., “A Beta-glucan-conjugate Vaccine and Anti-beta-glucan Antibodies are Effective Against Murine Vaginal Candidiasis as Assessed by a Novelin vivoImaging Technique,”Vaccine2010, 28:1717-1725.
Cassone Antonio
Polonellii Luciano
Gangle Brian J
Mondesi Robert B
Robins Roberta L.
Robins & Pasternak LLP
LandOfFree
Glucan-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucan-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucan-based vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4245830